TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39238042

Group type: EXPERIMENTAL
Intervention: Face-to-face interview for CDR-SB
Number of subjects: 139

Group type: COMPARATOR
Intervention: Medical record analysis for CDR-SB
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Face-to-face interview for 5-point scale CDR
Number of subjects: 139

Group type: COMPARATOR
Intervention: Medical record analysis for 5-point scale CDR
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Analysis by domain of the CDR
Number of subjects: 139
Study: 39238045

Group type: EXPERIMENTAL
Intervention: Hemiarch repair (HAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended arch repair (EAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 39238051

Group type: EXPERIMENTAL
Intervention: Pneumothorax present after CPR
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: History of obstructive lung disease
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Pneumothorax
Number of subjects: 237
Study: 39238059

Group type: EXPERIMENTAL
Intervention: Integrated telehealth intervention (Motivational and Cognitive-Behavioral Management for Alcohol and Pain [INTV])
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (CTL) condition
Number of subjects: 250
Study: 39238103

Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 60
Study: 39238110

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40-60 mg once daily for 10 days
Number of subjects: 77

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 77
Study: 39238363

Group type: EXPERIMENTAL
Intervention: Health workers' perspectives on quality measures for improving QMNC, including effective training on healthy women/newborns management (n=2748, 66.3%), availability of informed consent job aids (n=2770, 66.9%), and effective training on women/newborns rights (n=2714, 65.5%)
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: QMNC index score (0-400) calculated as a synthetic measure
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: Experience of care domain
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: Monthly linear decrease in QMNC index over time
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: HWs with <10 years of experience, HWs from public facilities, and midwives
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: Overall HWs' perspectives on QMNC
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: Staff censorship reported by HWs
Number of subjects: 4143
Study: 39238934

Group type: EXPERIMENTAL
Intervention: Novel social cognitive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified problem-solving training
Number of subjects: 0
Study: 39239186

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 160
Study: 39239277

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel and cisplatin (TP) followed by radiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TP plus PD-1 inhibition by pembrolizumab (MK-3475; 200 mg i.v. starting day 1 q3w for 17 cycles).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonresponders with ETSS < 30% or progressing disease).
Number of subjects: 0
Study: 39239332

Group type: EXPERIMENTAL
Intervention: Echocardiography-guided transapical radiofrequency ablation (TARFACT)
Number of subjects: 5
Study: 39239341

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 39239905

Group type: EXPERIMENTAL
Intervention: Multiplex apolipoprotein panel using LC-MS/MS
Number of subjects: 23376
Study: 39239939

Group type: EXPERIMENTAL
Intervention: Donor human milk
Number of subjects: 2296
Study: 39240359

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 662
Study: 39240498

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab and corticosteroids
Number of subjects: 0
Study: 39240508

Group type: EXPERIMENTAL
Intervention: Endobiliary radio-frequency ablation (EB-RFA) plus self-expandable metal stents (SEMS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Self-expandable metal stents (SEMS) alone
Number of subjects: 71
Study: 39240530

Group type: EXPERIMENTAL
Intervention: Travoprost FE implant
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Travoprost SE implant
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Sham/timolol
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: SE implant
Number of subjects: 1150
Study: 39240565

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 6100
Study: 39240566

Group type: COMPARATOR
Intervention: Normal nicotine content (NNC) cigarettes only
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes only
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: VLNC cigarettes plus e-cigarettes with classic tobacco flavor (VLNC + TF)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: VLNC cigarettes plus e-cigarettes with preferred flavors (VLNC + PF)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: NNAL levels in VLNC + PF condition
Number of subjects: 326
Study: 39240567

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for 3 days, then 0.5 mg daily thereafter)
Number of subjects: 4432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4432
Study: 39240681

Group type: EXPERIMENTAL
Intervention: SMART AMI-ACS smartphone app
Number of subjects: 0
Study: 39241203

Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles (including reTURBT)
Number of subjects: 31
Study: 39241208

Group type: EXPERIMENTAL
Intervention: True electroacupuncture
Number of subjects: 239

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 239
Study: 39241211

Group type: EXPERIMENTAL
Intervention: Imlunestrant monotherapy (n = 114)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Imlunestrant + abemaciclib (n = 42)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Imlunestrant + abemaciclib + aromatase inhibitor (AI) (n = 43)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Imlunestrant + everolimus (n = 42)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Imlunestrant + alpelisib (n = 21)
Number of subjects: 262
Study: 39241318

Group type: EXPERIMENTAL
Intervention: mRNA booster
Number of subjects: 50

Group type: COMPARATOR
Intervention: BBV152
Number of subjects: 50
Study: 39241341

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (AG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Classical massage (MG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90
Study: 39241562

Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Medical care as usual (MCAU) plus wait-list symptom monitoring (WL-SM)
Number of subjects: 37
Study: 39241807

Group type: EXPERIMENTAL
Intervention: Culture at 36.6°C
Number of subjects: 234

Group type: COMPARATOR
Intervention: Culture at 37.1°C
Number of subjects: 234
Study: 39241828

Group type: EXPERIMENTAL
Intervention: 72-hr octreotide infusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: 24-hr octreotide infusion
Number of subjects: 34
Study: 39241904

Group type: EXPERIMENTAL
Intervention: Etonogestrel implant + oral levonorgestrel (LNG)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: 52 mg levonorgestrel IUD
Number of subjects: 306
Study: 39241959

Group type: EXPERIMENTAL
Intervention: 6-year arm of adjuvant imatinib
Number of subjects: 136

Group type: COMPARATOR
Intervention: 3-year arm of adjuvant imatinib
Number of subjects: 136
Study: 39241963

Group type: EXPERIMENTAL
Intervention: GC + EBV-CTL (four cycles of gemcitabine and carboplatin followed by six cycles of EBV-CTL)
Number of subjects: 330

Group type: COMPARATOR
Intervention: GC (six cycles of gemcitabine and carboplatin)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: GC + EBV-CTL
Number of subjects: 330
Study: 39242029

Group type: EXPERIMENTAL
Intervention: 3D-3D registration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2D-3D registration
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3D-3D registration and 2D-3D registration
Number of subjects: 10
Study: 39242045

Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention to increase and maintain high fluid intake
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Self-reported stone events
Number of subjects: 1658
Study: 39242054

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2), dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39242065

Group type: EXPERIMENTAL
Intervention: 12-week program of supervised aerobic training (AT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AT and low to moderate-intensity strength training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AT and moderate to high-intensity strength training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Guideline-based physical activity and exercise recommendations
Number of subjects: 80
Study: 39242160

Group type: EXPERIMENTAL
Intervention: Genotype-guided (pharmacogenetic (PGx)-CDS) group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Genotype-guided group (high-risk patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard-of-care group (non-high-risk patients)
Number of subjects: 300
Study: 39242164

Group type: EXPERIMENTAL
Intervention: App-delivered self-management support (selfBACK) as an add-on to usual care
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 297
Study: 39242171

Group type: EXPERIMENTAL
Intervention: School-based deworming (SBD)
Number of subjects: 44574

Group type: EXPERIMENTAL
Intervention: Community-based deworming (CBD)
Number of subjects: 44574
Study: 39242247

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with focal boosts (60Gy in 20 fractions, boost dose up to 68Gy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with focal boosts
Number of subjects: 61
Study: 39242449

Group type: EXPERIMENTAL
Intervention: LVIS
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Enterprise
Number of subjects: 231
Study: 39242497

Group type: EXPERIMENTAL
Intervention: 30-day treatment with low-molecular weight heparin (dosage not specified)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment of 5000 IU low-molecular weight heparin daily from surgery until discharge (approximately 10 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30-day treatment with low-molecular weight heparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment of 5000 IU low-molecular weight heparin
Number of subjects: 100
Study: 39242499

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray (30 µg or 50 µg based on body weight)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray
Number of subjects: 159
Study: 39242508

Group type: EXPERIMENTAL
Intervention: Myosuit program (5 gait training sessions with Myosuit, followed by 6 weeks of home use)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional program (4 gait training sessions, followed by 6 weeks of home period)
Number of subjects: 34
Study: 39242877

Group type: EXPERIMENTAL
Intervention: 500 ml crystalloid fluid bolus (FB)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Follow-up strategy (FU)
Number of subjects: 130
Study: 39242999

Group type: EXPERIMENTAL
Intervention: Mentorship relationships
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Gender as a barrier
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Gender as a barrier for mentors of other genders
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Ethnicity as a barrier
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Barriers for white mentees
Number of subjects: 543
Study: 39243012

Group type: EXPERIMENTAL
Intervention: Outdoor Walk Group (OWG)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Workshop and 10 telephone reminders (WR)
Number of subjects: 190
Study: 39243031

Group type: EXPERIMENTAL
Intervention: CPAP treatment with unrestricted mask-access (34 different masks)
Number of subjects: 1484
Study: 39243058

Group type: EXPERIMENTAL
Intervention: Formulation-based cognitive behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General offender treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 0
Study: 39243075

Group type: EXPERIMENTAL
Intervention: Perennial malaria chemoprevention (PMC) using sulfadoxine-pyrimethamine (SP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 36
Study: 39243091

Group type: EXPERIMENTAL
Intervention: Kangaroo Care Group (KCG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: White Music Group (WMG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 90
Study: 39243100

Group type: EXPERIMENTAL
Intervention: LightGBM model
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: SnapLogisticRegression model
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: SnapDecisionTree model
Number of subjects: 6010
Study: 39243122

Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF)
Number of subjects: 170017
Study: 39243232

Group type: EXPERIMENTAL
Intervention: Highest CPB tertile
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Calcification presence
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Greater calcium burden
Number of subjects: 578
Study: 39243262

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR) using dedicated devices
Number of subjects: 279
Study: 39243264

Group type: EXPERIMENTAL
Intervention: T-TEER with the TriClip implant
Number of subjects: 98
Study: 39243268

Group type: EXPERIMENTAL
Intervention: LAMPOON (laceration of the anterior mitral leaflet)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LAMPOON
Number of subjects: 30
Study: 39243306

Group type: EXPERIMENTAL
Intervention: Pulsed field ablation (PFA)
Number of subjects: 32
Study: 39243304

Group type: EXPERIMENTAL
Intervention: Asciminib 80 mg once daily (q.d.)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Asciminib 40 mg twice daily (b.i.d.)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Asciminib 200 mg b.i.d.
Number of subjects: 353
Study: 39243311

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (35 mg twice daily, days -15 to -10) and decitabine (20 mg/m² daily, days -10 to -5) plus modified busulfan-cyclophosphamide (mBu/Cy) conditioning regimen
Number of subjects: 37
Study: 39243386

Group type: EXPERIMENTAL
Intervention: SB16
Number of subjects: 457

Group type: COMPARATOR
Intervention: DEN
Number of subjects: 457
Study: 39243397

Group type: EXPERIMENTAL
Intervention: IO + IO
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: IO + TKI
Number of subjects: 1362

Group type: COMPARATOR
Intervention: non-sRCC
Number of subjects: 1362
Study: 39243418

Group type: EXPERIMENTAL
Intervention: Surgery for LMBC
Number of subjects: 100
Study: 39243794

Group type: EXPERIMENTAL
Intervention: VLA1553
Number of subjects: 754
Study: 39243886

Group type: EXPERIMENTAL
Intervention: Medium-dose ExPEC10V (n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose ExPEC10V (n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pooled ExPEC10V group (medium- and high-dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ExPEC10V (medium- and high-doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ExPEC10V medium-dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ExPEC10V high-dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 24
Study: 39243979

Group type: EXPERIMENTAL
Intervention: Telehealth-only (THO)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 159
Study: 39244144

Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SGA)
Number of subjects: 1702

Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 1702
Study: 39244201

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BLa80 in maltodextrin (n=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 46
Study: 39244209

Group type: EXPERIMENTAL
Intervention: Niraparib plus Bevacizumab first-line maintenance therapy
Number of subjects: 59
Study: 39244480

Group type: EXPERIMENTAL
Intervention: Comfort scale
Number of subjects: 860

Group type: COMPARATOR
Intervention: NRS (Numerical Rating Scale)
Number of subjects: 860
Study: 39244490

Group type: EXPERIMENTAL
Intervention: SHJ002 ophthalmic solution (0.025%, 0.08%, and 0.25%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SHJ002 ophthalmic solution (0.25%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated eye (negative control)
Number of subjects: 12
Study: 39244530

Group type: EXPERIMENTAL
Intervention: Fentanyl inhalant (25μg/dose) administered via inhalation, up to six inhalations per episode with a minimum interval of 4 minutes between doses.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 59
Study: 39244532

Group type: EXPERIMENTAL
Intervention: SOC + ablative therapy (SABR preferred)
Number of subjects: 180

Group type: COMPARATOR
Intervention: SOC palliative-intent treatments
Number of subjects: 180
Study: 39244554

Group type: EXPERIMENTAL
Intervention: ECHO program
Number of subjects: 4340
Study: 39244595

Group type: EXPERIMENTAL
Intervention: TCZ (Tocilizumab) 8 mg/kg every 4 weeks to week 48
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: TCZ to week 24 followed by BAT1806/BIIB800 to week 48
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAT1806/BIIB800 to week 48
Number of subjects: 621

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 621
Study: 39244627

Group type: EXPERIMENTAL
Intervention: TAS-102, irinotecan, and bevacizumab
Number of subjects: 35
Study: 39244642

Group type: EXPERIMENTAL
Intervention: Autologous CD7 CAR-T cells
Number of subjects: 30
Study: 39244736

Group type: EXPERIMENTAL
Intervention: Leaf Expander®
Number of subjects: 150

Group type: COMPARATOR
Intervention: RME
Number of subjects: 150
Study: 39244893

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet treatment (DAPT)
Number of subjects: 678
Study: 39245025

Group type: EXPERIMENTAL
Intervention: Dynamic and Static Fatigue Index for gross and pinch-grip fatigability
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Static Fatigue Index for non-dominant side pinch grip
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Static Fatigue Index for non-dominant side gross grip
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dynamic Fatigue Index for dominant side pinch grip
Number of subjects: 23
Study: 39245031

Group type: EXPERIMENTAL
Intervention: Home-based CAB-LA PrEP care system
Number of subjects: 14
Study: 39245053

Group type: EXPERIMENTAL
Intervention: 10% aqueous povidone-iodine for skin preparation
Number of subjects: 5558

Group type: COMPARATOR
Intervention: 2% alcoholic chlorhexidine for skin preparation
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 5558

Group type: COMPARATOR
Intervention: Uncoated sutures
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: ASA grade III-V
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Presence of diabetes
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Being an ex-smoker
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 5558

Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 5558
Study: 39245055

Group type: EXPERIMENTAL
Intervention: mRNA-1011.1 (pentavalent; containing one additional A/H3N2 strain [Newcastle])
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: mRNA-1011.2 (quadrivalent; B/Yamagata replaced with one additional A/H3N2 strain [Newcastle])
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 50.0 μg
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 62.5 μg
Number of subjects: 696

Group type: COMPARATOR
Intervention: mRNA-1010 (control group)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Solicited adverse reactions
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Unsolicited adverse events
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Safety population
Number of subjects: 696
Study: 39245060

Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (8 Gy) plus best supportive care
Number of subjects: 66

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 66
Study: 39245178

Group type: EXPERIMENTAL
Intervention: 1-Hz TMS
Number of subjects: 41

Group type: COMPARATOR
Intervention: 10-Hz TMS
Number of subjects: 41
Study: 39245182

Group type: EXPERIMENTAL
Intervention: Yolk-AKD
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: White-AKD
Number of subjects: 76

Group type: COMPARATOR
Intervention: BLC
Number of subjects: 76
Study: 39245341

Group type: EXPERIMENTAL
Intervention: Hybrid combination of ProGlide (PP) and Angio-Seal (AS)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Dual ProGlide (PP)
Number of subjects: 257